The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials
Open accessAbstract
The Dominantly Inherited Alzheimer Network (DIAN) is an international registry of individuals at risk for developing autosomal dominant Alzheimer's disease (AD). Its primary aims are to investigate the temporal ordering of AD pathophysiological changes that occur in asymptomatic mutation carriers and to identify those markers that herald the transition from cognitive normality to symptomatic AD. DIAN participants undergo longitudinal evaluations, including clinical and cognitive assessments and measurements of molecular and imaging AD biomarkers. This review details the unique attributes of DIAN as a model AD biomarker study and how it provides the infrastructure for innovative research projects, including clinical trials. The recent design and launch of the first anti-amyloid-beta secondary prevention trial in AD, led by the related DIAN Trials Unit, also are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DIAN participants are members of families carrying highly penetrant autosomal-dominant mutations in the genes encoding the amyloid beta precursor protein (APP) or presenilin 1 (PSEN1) or 2 (PSEN2)19.”
From Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) · cites this paper as [19]
In the citing paper
“Autosomal dominant AD (ADAD) is well suited to study biomarker trajectories due to the virtually complete penetrance of the mutations and consistency of symptom onset within families4,5.”
From Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“Even with the publication of the National Institute on Aging (NIA)-Alzheimer’s Association diagnostic criteria and guidelines for preclinical AD, mild cognitive impairment (MCI) due to AD, and symptomatic AD [33-35], many researchers and clinicians still consider the term preclinical AD to encompass prodromal AD, MCI,…”
BackgroundSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationAlbert, M., DeKosky, S. T., Dickson, D. W., Dubois, B., Feldman, H., Fox, N. C., Gamst, A. C., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.11.1.96 · Cited by 2,643
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
Gómez-Isla, T., Price, J. L., McKeel Jr., D. W., Morris, J. C., Growdon, J. H., & Hyman, B. T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04491.1996 · Cited by 1,796 · cited 1×
“AD pathology is present in the brain many years before the onset of clinical symptoms [5-11].”
BackgroundSelf-citationAlzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424
Self-citation
Cited by
Sorted by citations
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Self-citationAmyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
“In 2012, DIAN-TU launched the first prevention trial focusing on two drugs: gantenerumab (against Aβ aggregates) and solanezumab (against soluble Aβ monomers).(337) The data showed that gantenerumab had a positive impact on the reduction of cortical amyloid, leading to its further study by an exploratory open-label ex…”
BackgroundInfluentialDominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927
Self-citationTau and neurodegenerative disease: the story so far
Iqbal, K., Liu, F., & Gong, C.-X. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.225 · Cited by 806
Alzheimer’s disease prevention: from risk factors to early intervention
Crous‐Bou, M., Minguillón, C., Gramunt, N., & Molinuevo, J. L. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0297-z · Cited by 730
Lanoiselée, H.-M., Nicolas, G., Wallon, D., Rovelet-Lecrux, A., Lacour, M., Rousseau, S., Richard, A.-C., Pasquier, F., Rollin-Sillaire, A., Martinaud, O., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002270 · Cited by 616
Gordon, B. A., Blazey, T. M., Su, Y., Hari-Raj, A., Dincer, A., Flores, S., Christensen, J., McDade, E., Wang, G., Xiong, C., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30028-0 · Cited by 602
Self-citationSymptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis
Ryman, D. C., Acosta-Baena, N., Aisen, P. S., Bird, T., Danek, A., Fox, N. C., Goate, A., Frommelt, P., Ghetti, B., Langbaum, J. B. S., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000596 · Cited by 502
Self-citationAlzheimer’s Disease Genetics: From the Bench to the Clinic
Karch, C. M., Cruchaga, C., & Goate, A. M. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.041 · Cited by 473
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
Salloway, S., Farlow, M., McDade, E., Clifford, D. B., Wang, G., Llibre-Guerra, J. J., Hitchcock, J. M., Mills, S. L., Santacruz, A. M., Aschenbrenner, A. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01369-8 · Cited by 359
Self-citationAlzheimer's disease associated with Down syndrome: a genetic form of dementia
Fortea, J., Zaman, S. H., Hartley, S., Rafii, M. S., Head, E., & Carmona-Iragui, M. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00245-3 · Cited by 357
Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease
Baranello, R., Bharani, K., Padmaraju, V., Chopra, N., Lahiri, D., Greig, N., Pappolla, M., & Sambamurti, K. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666141218140953 · Cited by 331
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores
de Rojas, I., Moreno-Grau, S., Tesi, N., Grenier-Boley, B., Andrade, V., Jansen, I. E., Pedersen, N. L., Stringa, N., Zettergren, A., Hernández, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22491-8 · Cited by 324
Bateman, R. J., Benzinger, T. L., Berry, S., Clifford, D. B., Duggan, C., Fagan, A. M., Fanning, K., Farlow, M. R., Hassenstab, J., McDade, E. M., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.07.005 · Cited by 303
Self-citationvan der Lee, S. J., Wolters, F. J., Ikram, M. K., Albert Hofman, D., Ikram, M. A., Amin, N., & van Duijn, C. M. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30053-x · Cited by 317
iPS cell technologies: significance and applications to CNS regeneration and disease
Okano, H., & Yamanaka, S. (2014) · Molecular Brain · doi:10.1186/1756-6606-7-22 · Cited by 236
Gordon, B. A., Blazey, T. M., Christensen, J., Dincer, A., Flores, S., Keefe, S., Chen, C., Su, Y., McDade, E. M., Wang, G., et al. (2019) · Brain · doi:10.1093/brain/awz019 · Cited by 180
Self-citationPast, present and future role of retinal imaging in neurodegenerative disease
Kashani, A. H., Asanad, S., Chan, J. W., Singer, M., Zhang, J., Sharifi, M., Khansari, M. M., Abdolahi, F., Shi, Y., Biffi, A., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100938 · Cited by 169
Shea, Y. F., Chu, L., Chan, A. O.-K., Ha, J. C. T., Li, Y., & Song, Y. (2015) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2015.08.004 · Cited by 148
Segregation of functional networks is associated with cognitive resilience in Alzheimer’s disease
Ewers, M., Luan, Y., Frontzkowski, L. K., Neitzel, J., Rubinski, A., Dichgans, M., Hassenstab, J. J., Gordon, B. A., Chhatwal, J. P., Levin, J., et al. (2021) · Brain · doi:10.1093/brain/awab112 · Cited by 146
Self-citationWeiner, M. W., Nosheny, R. L., Camacho, M. R., Truran‐Sacrey, D., Mackin, R. S., Flenniken, D., Ulbricht, A., Insel, P. S., Finley, S., Fockler, J., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.02.021 · Cited by 135
Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease
Thomas, J. B., Brier, M. R., Bateman, R. J., Snyder, A. Z., Benzinger, T. L., Xiong, C., Raichle, M., Holtzman, D. M., Sperling, R. A., Mayeux, R., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1654 · Cited by 129
Self-citationGenetic diagnosis and prognosis of Alzheimer’s disease: challenges and opportunities
Reitz, C. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1002469 · Cited by 125
Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years
Albert, M., Zhu, Y., Moghekar, A., Mori, S., Miller, M. I., Soldan, A., Pettigrew, C., Selnes, O., Li, S., & Wang, M.-C. (2018) · Brain · doi:10.1093/brain/awx365 · Cited by 118
Challenges of modifying disease progression in prediagnostic Parkinson's disease
Salat, D., Noyce, A. J., Schrag, A. E., & TOLOSA, E. S. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00060-0 · Cited by 119
Franzmeier, N., Düzel, E., Jessen, F., Büerger, K., Levin, J., Duering, M., Dichgans, M., Haass, C., Suárez‐Calvet, M., Fagan, A. M., et al. (2018) · Brain · doi:10.1093/brain/awy008 · Cited by 117
Self-citationAdvances in the prevention of Alzheimer's Disease
Sindi, S., Mangialasche, F., & Kivipelto, M. (2015) · F1000Prime Reports · doi:10.12703/p7-50 · Cited by 118
Toward precision medicine in Alzheimer’s disease
Reitz, C. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.03.05 · Cited by 100
Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer’s Disease
Chouraki, V., for the International Genomics of Alzheimer’s Project, Reitz, C., Maury, F., Bis, J. C., Bellenguez, C., Yu, L., Jakobsdottir, J., Mukherjee, S., Adams, H. H., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150749 · Cited by 98
Anti-Viral Properties of Amyloid-β Peptides
Bourgade, K., Dupuis, G., Frost, E. H., & Fülöp, T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160517 · Cited by 97
Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward
Hsu, D. C., & Marshall, G. A. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160930112125 · Cited by 95
Plasma biomarkers predict Alzheimer’s disease before clinical onset in Chinese cohorts
Cai, H., Pang, Y., Fu, X., Ren, Z., & Jia, L. (2023) · Nature Communications · doi:10.1038/s41467-023-42596-6 · Cited by 95
CAP—advancing the evaluation of preclinical Alzheimer disease treatments
Reiman, E. M., Langbaum, J. B. S., Tariot, P. N., Lopera, F. J., Bateman, R. J., Morris, J. C., Sperling, R. A., Aisen, P. S. S., Roses, A. D., Welsh-Bohmer, K. A., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.177 · Cited by 92
Self-citationAdaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development
Paganoni, S., Berry, J. D., Quintana, M., Macklin, E. A., Saville, B. R., Detry, M. A., Chase, M. K., Sherman, A., Yu, H., Drake, K., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26285 · Cited by 89
Franzmeier, N., Ren, J., Damm, A., Monté, G. C., Boada, M., Ruiz, A., Ramı́rez, A., Jessen, F., Düzel, E., Rodríguez‐Gómez, O., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0404-6 · Cited by 86
Self-citationPanza, F., Solfrizzi, V., Imbimbo, B. P., & Logroscino, G. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.935332 · Cited by 80
Understanding the cause of sporadic Alzheimer’s disease
Zetterberg, H., & Mattsson, N. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.915740 · Cited by 73
Presymptomatic cortical thinning in familial Alzheimer disease
Weston, P. S. J., Nicholas, J. M., Lehmann, M., Ryan, N. S., Liang, Y., Macpherson, K., Marc Modat, A., Rossor, M. N., Schott, J. M., Sebastien Ourselin, A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003322 · Cited by 71
Bateman, R. J., Li, Y., McDade, E., Llibre‐Guerra, J. J., Clifford, D. B., Atri, A., Mills, S. L., Santacruz, A. M., Wang, G., Supnet, C. B., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00024-9 · Cited by 71
Self-citationMorris, J. C., Weiner, M., Xiong, C., Beckett, L., Coble, D., Saito, N., Aisen, P. S., Allegri, R., Benzinger, T. L. S., Berman, S. B., et al. (2022) · Brain · doi:10.1093/brain/awac181 · Cited by 68
Self-citationMallik, A. K., Drzezga, A. E., & Minoshima, S. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.005 · Cited by 64
Jiménez-Mesa, C., Arco, J. E., Martínez-Murcia, F. J., Suckling, J., Ramı́rez, J., & Górriz, J. M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106984 · Cited by 62
Molinuevo, J. L., Camı́, J., Carné, X., Carrillo, M. C., Georges, J., Isaac, M., Khachaturian, Z. S., Kim, S. Y. H., Morris, J. C., Pasquier, F., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.01.009 · Cited by 63
Self-citationAn intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice
Cheng, Y.-S., Chen, Z.-T., Liao, T., Lin, C. W., Shen, H. C.-H., Wang, Y., Chang, C., Liu, R., Chen, R. P. ‐., & Tu, P. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606666 · Cited by 60
Schultz, S. A., Strain, J. F., Adedokun, A., Wang, Q., Preische, O., Kühle, J., Flores, S. E., Keefe, S., Dincer, A., Ances, B. M., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104960 · Cited by 58
Self-citationFinsterwalder, S., Vlegels, N., Gesierich, B. G., Caballero, M. Á. A., Weaver, N. A., Franzmeier, N., Georgakis, M. K., Konieczny, M. J., Koek, H. L., Dominantly Inherited Alzheimer Network (DIAN), et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12150 · Cited by 58
Bussy, A., Snider, B. J., Coble, D. W., Xiong, C., Fagan, A. M., Cruchaga, C., Benzinger, T. L. S., Gordon, B. A., Hassenstab, J. J., Bateman, R. J., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.10.011 · Cited by 57
Self-citationKatzorke, A., Zeller, J. B. M., Müller, L. D., Lauer, M., Polak, T. T., Deckert, J., & Herrmann, M. J. (2018) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2018.02.003 · Cited by 54
Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease
Panza, F., Solfrizzi, V., Imbimbo, B. P., Giannini, M., Santamato, A., Seripa, D., & Logroscino, G. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.945522 · Cited by 51
Changes in Frailty Predict Changes in Cognition in Older Men: The Honolulu-Asia Aging Study
Armstrong, J. J., Godin, J., Launer, L. J., White, L. R., Mitnitski, A., Rockwood, K. J., & Andrew, M. K. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151172 · Cited by 51
Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer’s disease
Müller, S., Preische, O., Sohrabi, H. R., Gräber, S., Jucker, M., Dietzsch, J., Ringman, J. M., Martins, R. N., McDade, E., Schofield, P. R., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01327-w · Cited by 49
Self-citationJoseph‐Mathurin, N., Llibre‐Guerra, J. J., Li, Y., McCullough, A. A., Hofmann, C., Wojtowicz, J., Park, E., Wang, G., Preboske, G. M., Wáng, Q., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26511 · Cited by 48
Self-citationTorshizi, A. D., & Wang, K. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.015 · Cited by 47
From beta amyloid to altered proteostasis in Alzheimer’s disease
Bruni, A. C., Bernardi, L., & Gabelli, C. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101126 · Cited by 47
ENDPOINTS FOR PRE-DEMENTIA AD TRIALS: A REPORT FROM THE EU/US/CTAD TASK FORCE
Vellas, B. J., Bateman, R. J., Blennow, K., Frisoni, G. B., Johnson, K. A., Katz, R. G., Langbaum, J. B. S., Marson, D. C., Sperling, R. A., Wessels, A. M., et al. (2015) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2015.55 · Cited by 47
Self-citationPanza, F., Seripa, D., Lozupone, M., Solfrizzi, V., Imbimbo, B. P., Barulli, M. R., Tortelli, R., Capozzo, R., Bisceglia, P., Dimitri, A., et al. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389885 · Cited by 41
Fernández, M. V., Liu, M., Beric, A., Johnson, M., Cetin, A., Patel, M. R., Budde, J., Kohlfeld, P., Bergmann, K., Lowery, J., et al. (2024) · Scientific Data · doi:10.1038/s41597-024-03485-9 · Cited by 41
Self-citationSchindler, S. E., & Fagan, A. M. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00142 · Cited by 40
Llibre‐Guerra, J. J., Li, Y., Schindler, S. E., Gordon, B. A., Fagan, A. M., Morris, J. C., Benzinger, T. L. S., Hassenstab, J. J., Wang, G., Allegri, R., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.17126 · Cited by 40
Self-citationComparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease
Dincer, A., Gordon, B. A., Hari‐Raj, A., Keefe, S., Flores, S. E., McKay, N. S., Paulick, A. M., Shady, K., Feldman, R. L., Hornbeck, R. C., et al. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102491 · Cited by 36
Self-citationMontine, T. J., & Montine, K. S. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150656 · Cited by 34
Cerebrospinal fluid analysis in Alzheimer’s disease: technical issues and future developments
Lista, S., Zetterberg, H., Dubois, B., Blennow, K., & Hampel, H. J. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7366-z · Cited by 35
Diminishing return for mechanistic therapeutics with neurodegenerative disease duration?
Rubinsztein, D. C., & Orr, H. T. (2016) · BioEssays · doi:10.1002/bies.201600048 · Cited by 33
Genetic origin of a large family with a novel PSEN1 mutation (Ile416Thr)
Aguilar, L. R., Acosta‐Uribe, J., Giraldo, M., Moreno, S., Baena, A. Y., Alzate, D., Cuastumal, A. R., Aguillon, D. F., Madrigal, L., Saldarriaga, A., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.12.010 · Cited by 31
Trambauer, J., Sarmiento, R. M. R., Fukumori, A., Feederle, R., Baumann, K., & Steiner, H. (2019) · EMBO Reports · doi:10.15252/embr.201947996 · Cited by 31
A critical appraisal of blood-based biomarkers for Alzheimer’s disease
Lista, S., Mapstone, M. E., Caraci, F., Emanuele, E., López‐Ortiz, S., Martín-Hernández, J., Triaca, V., Imbimbo, C., Gabelle, A., Mielke, M. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102290 · Cited by 30
O’Connor, A., Weston, P. S. J., Pavisic, I. M., Ryan, N. S., Collins, J. D., Lu, K., Crutch, S. J., Alexander, D. C., Fox, N. C., & Oxtoby, N. P. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00695-2 · Cited by 30
Imaging as a biomarker in drug discovery for Alzheimer’s disease: is MRI a suitable technology?
Pich, E. M., Jeromin, A., Frisoni, G. B., Hill, D., Lockhart, A., Schmidt, M. E., Turner, M. R., Mondello, S., & Potter, W. Z. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt276 · Cited by 30
Llibre‐Guerra, J. J., Li, Y., Allegri, R., Méndez, P. C., Surace, E. I., Rodríguez, J. J. L., Sosa, A. L., Aláez‐Verson, C., Longoria-Ibarrola, E. M., Téllez‐Martínez, J. A., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12227 · Cited by 29
Self-citationPathogenic variants in the Longitudinal Early‐onset Alzheimer's Disease Study cohort
Nudelman, K. N. H., Jackson, T., Rumbaugh, M. C., Eloyan, A., Abreu, M., Dage, J. L., Snoddy, C., Faber, K. M., Foroud, T., Hammers, D. B., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13482 · Cited by 28
Sosa, A. L., Brucki, S. M. D., Crivelli, L., Lopera, F. J., Acosta, D. M., Acosta‐Uribe, J., Aguilar, D., Aguilar-Navarro, S. G., Allegri, R., Bertolucci, P. H. F., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13850 · Cited by 30
Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies
Golde, T. E. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13583 · Cited by 29
Trambauer, J., Fukumori, A., & Steiner, H. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2020.01.011 · Cited by 28
11C-PiB PET can underestimate brain amyloid-β burden when cotton wool plaques are numerous
Abrahamson, E. E., Kofler, J., Becker, C. R., Price, J. C., Newell, K. L., Ghetti, B. F., Murrell, J. R., McLean, C., López, O. L., Mathis, C. A., et al. (2021) · Brain · doi:10.1093/brain/awab434 · Cited by 28
Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning
Castillo-Barnés, D., Su, L., Ramírez, J., Salas-Gonzalez, D., Martínez-Murcia, F. J., Illán, I. A., Segovia, F., Ortíz, A., Cruchaga, C., Farlow, M. R., et al. (2020) · Information Fusion · doi:10.1016/j.inffus.2020.01.001 · Cited by 29
Challenges of Integrative Disease Modeling in Alzheimer's Disease
Khatami, S. G., Robinson, C., Birkenbihl, C., Domingo‐Fernándéz, D., Hoyt, C. T., & Hofmann‐Apitius, M. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00158 · Cited by 28
δ-COP modulates Aβ peptide formation via retrograde trafficking of APP
Bettayeb, K., Chang, J. C., Luo, W., Aryal, S., Varotsis, D. F., Randolph, L. K., Netzer, W. J., Greengard, P., & Flajolet, M. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604156113 · Cited by 26
Takamatsu, Y., Ho, G. J., Koike, W., Sugama, S., Takenouchi, T., Waragai, M., Wei, J., Sekiyama, K., & Hashimoto, M. (2017) · npj Parkinson s Disease · doi:10.1038/s41531-016-0001-1 · Cited by 26
The landscape of autosomal-dominant Alzheimer’s disease: global distribution and age of onset
Liu, H., Marsh, T. W., Shi, X., Renton, A. E., Bowling, K. M., Ziegemeier, E., Wang, G., Cao, Y., Aristel, A., Li, J., et al. (2025) · Brain · doi:10.1093/brain/awaf038 · Cited by 25
Self-citationClinical heterogeneity in familial Alzheimer’s disease
van der Flier, W. M. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30275-7 · Cited by 23
Cerebrospinal Fluid Biomarkers in Familial Forms of Alzheimer's Disease and Frontotemporal Dementia
Rostgaard, N., Waldemar, G., Nielsen, J. E., & Simonsen, A. H. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000381828 · Cited by 23
Exosome release and cargo in Down syndrome
Hamlett, E. D., LaRosa, A., Mufson, E. J., Fortea, J., Ledreux, A., & Granholm, A. (2019) · Developmental Neurobiology · doi:10.1002/dneu.22712 · Cited by 21
Moga, D. C., Beech, B. F., Abner, E. L., Schmitt, F. A., Khouli, R. H. E., Martinez, A. I., Eckmann, L., Huffmyer, M. J., George, R., & Jicha, G. A. (2019) · Trials · doi:10.1186/s13063-019-3993-0 · Cited by 22
Prescott, J. W., Doraiswamy, P. M., Gamberger, D., Benzinger, T. L. S., Petrella, J. R., & for the Dominantly Inherited Alzheimer Network (2021) · Radiology · doi:10.1148/radiol.2021210383 · Cited by 21
Nanomedicine against Alzheimer’s and Parkinson’s Disease
Tandon, A., Singh, S. J., & Chaturvedi, R. K. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201021140904 · Cited by 20
Llibre‐Guerra, J. J., Iaccarino, L., Coble, D., Edwards, L., Li, Y., McDade, E., Strom, A., Gordon, B. A., Mundada, N. S., Schindler, S. E., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad280 · Cited by 21
Self-citationUpdate on Disease-Modifying/Preventive Therapies in Alzheimer’s Disease
Apter, J. T., Shastri, K., & Pizano, K. (2015) · Current Geriatrics Reports · doi:10.1007/s13670-015-0141-x · Cited by 18
Polak, T. T., Herrmann, M. J., Müller, L. D., Zeller, J. B. M., Katzorke, A., Fischer, M., Spielmann, F., Weinmann, E., Hommers, L. G., Lauer, M., et al. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1781-0 · Cited by 18
Grill, J. D., Bateman, R. J., Buckles, V., Oliver, A., Morris, J. C., Masters, C. L., Klunk, W. E., Ringman, J. M., & for the Dominantly Inherited Alzheimer’s Network (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0135-0 · Cited by 18
Self-citationBarriers to Effective Memory Assessments for Alzheimer’s Disease
Parra, M. A. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215445 · Cited by 17
Abnormal retinal capillary blood flow in autosomal dominant Alzheimer's disease
Singer, M., Ringman, J. M., Chu, Z., Zhou, X., Jiang, X., Shahidzadeh, A., Wang, R. K., & Kashani, A. H. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12162 · Cited by 16
White Matter Abnormalities Track Disease Progression in PSEN1 Autosomal Dominant Alzheimer’s Disease
Sánchez‐Valle, R., Monté, G. C., Sala‐Llonch, R., Bosch, B., Fortea, J., Lladó, A., Antonell, A., Balasa, M., Bargalló, N., & Molinuevo, J. L. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150899 · Cited by 16
A pathogenic PSEN1 Trp165Cys mutation associated with early-onset Alzheimer’s disease
Giau, V. V., Pyun, J., Suh, J., Bagyinszky, E., An, S. S. A., & Kim, S. (2019) · BMC Neurology · doi:10.1186/s12883-019-1419-y · Cited by 15
Genetic Heterogeneity of Alzheimer’s Disease: Embracing Research Partnerships
Nacmias, B., Bagnoli, S., Piaceri, I., & Sorbi, S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170570 · Cited by 14
Carmona‐Iragui, M., O’Connor, A., Llibre‐Guerra, J. J., Lao, P. J., Ashton, N. J., Fortea, J., & Sánchez‐Valle, R. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105327 · Cited by 13
Reiman, E. M., Pruzin, J. J., Ríos‐Romenets, S., Brown, C., Giraldo, M., Acosta‐Baena, N., Tobón, C., Hu, N., Chen, Y., Ghisays, V., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12843 · Cited by 13
Warren‐Gash, C., Cadogan, S. L., Nicholas, J. M., Breuer, J. M., Shah, D., Pearce, N., Shiekh, S., Smeeth, L., Farlow, M. R., Mori, H., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51669 · Cited by 11
Self-citation15 years of longitudinal genetic, clinical, cognitive, imaging, and biochemical measures in DIAN
Daniels, A. J., McDade, E., Llibre‐Guerra, J. J., Xiong, C., Perrin, R. J., Ibáñez, L., Supnet‐Bell, C., Cruchaga, C., Goate, A., Renton, A. E., et al. (2026) · npj Dementia · doi:10.1038/s44400-025-00047-7 · Cited by 11
Self-citationProof of concept demonstration of optimal composite MRI endpoints for clinical trials
Edland, S. D., Ard, M. C., Sridhar, J., Cobia, D. J., Martersteck, A., Mesulam, M. M., & Rogalski, E. J. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.05.002 · Cited by 11
The amyloid hypothesis is too good to be true
Kurkinen, M. T. (2017) · Alzheimer s Dementia & Cognitive Neurology · doi:10.15761/adcn.1000106 · Cited by 11
Metadata
- Authors
- Moulder, K. L., Snider, B., Mills, S. L., Buckles, V. D., Santacruz, A. M., Bateman, R. J., & Morris, J. C.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Bateman, Randall J
- Morris, John C
- Venue
- Alzheimer's Research & Therapy
- Published
- 2013
- Volume
- 5
- Issue
- 5
- Pages
- 48
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC3978584
- OpenAlex
- W2110630889
- Cited by
- 142
- References
- 44
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 10 · 2023: 6 · 2022: 8 · 2021: 10 · 2020: 12 · 2019: 14 · 2018: 9 · 2017: 12 · 2016: 21 · 2015: 16 · 2014: 11
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Alzheimer s Research & Therapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- Deutsches Zentrum für Neurodegenerative Erkrankungen
- National Institute on Aging (U19AG032438)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- autosomal dominant Alzheimer's disease, mutation carriers, Alzheimer's disease biomarkers, preclinical Alzheimer's disease, longitudinal assessment, clinical trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
